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Genome engineering with programmable nucleases depends on cellular responses to a targeted double-
strand break (DSB). The first truly targetable reagents were the zinc finger nucleases (ZFNs) showing that
arbitrary DNA sequences could be addressed for cleavage by protein engineering, ushering in the break-
through in genomemanipulation. ZFNs resulted from basic research on zinc finger proteins and the FokI restriction
enzyme (which revealed a bipartite structure with a separable DNA-binding domain and a non-specific cleavage
domain). Studies on the mechanism of cleavage by 3-finger ZFNs established that the preferred substrates were
paired binding sites, which doubled the size of the target sequence recognition from 9 to 18 bp, long enough to
specify a unique genomic locus in plant andmammalian cells. Soon afterwards, a ZFN-inducedDSBwas shown to
stimulate homologous recombination in cells. Transcription activator-like effector nucleases (TALENs) that are
based on bacterial TALEs fused to the FokI cleavage domain expanded this capability. The fact that ZFNs and
TALENs have been used for genomemodification of more than 40 different organisms and cell types attests to the
success of protein engineering. The most recent technology platform for delivering a targeted DSB to cellular
genomes is that of the RNA-guided nucleases, which are based on the naturally occurring Type II prokaryotic
CRISPR-Cas9 system. Unlike ZFNs and TALENs that use protein motifs for DNA sequence recognition,
CRISPR-Cas9 depends on RNA–DNA recognition. The advantages of the CRISPR-Cas9 system—the ease of
RNA design for new targets and the dependence on a single, constant Cas9 protein—have led to its wide adoption
by research laboratories around the world. These technology platforms have equipped scientists with an
unprecedented ability to modify cells and organisms almost at will, with wide-ranging implications across biology
and medicine. However, these nucleases have also been shown to cut at off-target sites with mutagenic
consequences. Therefore, issues such as efficacy, specificity and delivery are likely to drive selection of reagents
for particular purposes. Human therapeutic applications of these technologies will ultimately depend on risk versus
benefit analysis and informed consent.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
With the advent of high-throughput DNA sequenc-
ing and powerful computer algorithms, the genome
sequences of many organisms, including human,
have been deciphered. However, understanding the
functions of the genes requires sequence editing
either by deleting or by modifying them individually
and then studying the resulting mutant phenotypes.Authors. Published by Elsevier Ltd. This
rg/licenses/by-nc-nd/4.0/).The programmable nucleases take advantage of
natural cellular pathways of DNA repair for the intro-
duction targeted sequence changes.
DNA double-strand breaks (DSBs) are potentially
lethal to cells, which have two broad classes of
mechanisms to repair them: non-homologous end
joining (NHEJ) and homology-directed repair (HDR).
NHEJ often results in variable lengths of insertion and
deletion mutations (indels) and thus can be used tois an open access article under the CC BY-NC-ND license
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964 Review: Programmable Nucleases for Genome Engineeringknockout genes (Fig. 1). Nuclease-induced breaks are
efficiently mutated likely because perfectly re-joined
sequences can andwill be re-cleaved until they acquire
an indel, at which point they can no longer be cleaved.
HDR normally relies on recombination with homolo-
gous sequences in anundamagedchromatid, but it can
be diverted to use a homologous donor DNA template
provided by the experimenter. This leads to the
introduction of precise alterations to the genome,
which are specified by the template (Fig. 1). Gene
targeting by HDR is not an efficient process in cells of
higher eukaryotes—typically only one in approximately
a million treated cells undergoes the desired genome
modification [1,2].
Experiments using rare-cutting meganucleases
(e.g., I-SceI) [3] showed that stimulation of both
local mutagenesis and incorporation of homologous
donor sequences can be achieved by inducing an
intentional DSB. Restriction endonucleases, the mo-
lecular scissors that revolutionized molecular biology
and the biotechnology industry in the seventies by
enabling cloning, are not useful for delivering a targeted
chromosomal DSB, since they recognize short DNA
sites (usually 4- to 8-bp sites), which occur much too
frequently within most genomes. The recognition
specificity of meganucleases proved too difficult to
tailor to desired target sites. Thus, generation of a
targeted DSB remained the rate-limiting step in the
development of HDR technology for genome engineer-
ing of plant and mammalian cells, including human
cells. Therefore, techniques had to be developed for a
generalmeansof delivering a targeted genomicDSBat
a unique chromosomal locus in order to stimulate HDR
at that site with exogenously added donor DNA.
This article gives our personal perspectives on the
origins of programmable nucleases [zinc finger
nucleases (ZFNs), transcription activator-like effector
nucleases (TALENs) and RNA-guided CRISPR-
Cas9] for genome engineering, highlights key mile-
stone publications of the field (Fig. 2) and discussesu
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athe biological and medical applications of these
technologies.
Reflections on the Origins of Programmable
Nucleases and Their Applications to Human
GenomeEngineering—SrinivasanChandrasegaran
In 1986, as a newly hired assistant professor with
an independent laboratory in the Department of
Environmental Health Sciences at the Johns Hop-
kins School of Public Health, I initiated the research
on chimeric restriction enzymes with the aim to
generate designer site-specific endonucleases that
could target specific genes within cells. Type II
restriction enzymes are not useful for this task, since
they typically recognize 4- to 8-bp palindromic DNA
sites and on average cut DNA once every 4096–
65,536 bases [4]. For genome engineering, we
needed enzymes that recognize sequences of 16–
18 bp in length to make a unique targeted DSB
within the human genome of 3 × 109 bp. Therefore,
a long-term goal of the restriction–modification
(R–M) enzyme field had been to generate novel
restriction endonucleases with longer recognition
sites either by mutating or by engineering existing
Type II enzymes.
Functional domains in FokI restriction endonuclease
Restriction enzymes have a dual function, namely
DNA recognition and DNA cleavage. In the case of
Type II enzymes, these functions overlap each other.
Attempts to generate new specificities, particularly
longer recognition sites, by genetic manipulation of
theexistingType II enzymeswereunsuccessful. This is
probably due to the fact that multiple mutations are
needed before a change in specificity can be achieved.
Alternatively, since the DNA recognition and catalytic
functions overlap each other in Type II enzymes,
attempts to changeamino acid residues responsible for
Fig. 2. Publication milestones for genome engineering using programmable nucleases.
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activity. Changes in the DNA-binding domain may
alter the geometry of the catalytic sites, which is likely
accompanied by a drop in cleavage activity by several
orders of magnitude making the mutant enzymes
inactive. Therefore, we reasoned that the common
Type II enzymes are not the best substrates for
changing sequence specificity.
To circumvent this problem, we chose to study a
Type IIS restriction enzyme, FokI, that recognizes
the non-palindromic pentadeoxyribonucleotide
5′-GGATG-3′:5′-CATCC-3′ in duplex DNA and
cleaves 9/13 nucleotides downstream of the recog-
nition site. We speculated that two separable protein
domains are likely to be present within FokI: one for
sequence-specific recognition of DNA (FR) and the
other one for the endonuclease activity (FN). Once
the DNA-binding domain is anchored at the recog-
nition site, a signal is transmitted to the endonucle-
ase domain probably through allosteric interactions,
for the cleavage to occur. If this were the case, we
reasoned that the Type IIS enzymes are the ideal
candidates for changing sequence specificities
because one may be able to swap the recognition
domains with other naturally existing DNA-binding
proteins that recognize longer sequences.
Since none of the Type IIS R–M systems was
cloned at that time, we started by cloning the FokI
R–M system from Flavobacterium okeanokoites (Wu
and Chandrasegaran, 1989, unpublished results).
Two other laboratories also independently cloned
the FokI R–M system [5,6]. We used PCR to
re-design the FokI endonuclease gene to over-
express the 66-kDa enzyme in Escherichia coli to
obtain ~50 mg/L of the purified enzyme. Theprevailing opinion at that time was that FokI, which
recognizes an asymmetric sequence and is about
twice as large as the Type II enzymes (like EcoRI
and BamHI), functions as a monomer while the Type
II enzymes that recognize a symmetric sequence
function as homodimers.
We performed proteolytic fragment analysis of
FokI endonuclease using trypsin, which revealed a
separable 41-kDa N-terminal DNA-binding domain
(FR) and a 25-kDa C-terminal domain (FN) with
non-specific DNA cleavage activity [7]. We con-
firmed the results by making C-terminal deletion
mutants of FokI restriction endonuclease [8]. We
then extended the predicted α-helix linker at the
junction of the DNA-binding domain and the cleav-
age domain by one turn by inserting 4 amino acids
into native FokI to move the cut site further
downstream by 1 bp, that is, from 9/13 bp (for the
native enzyme) to 10/14 bp (for the mutant enzyme)
[9,10]. This further confirmed the boundaries of the
functional domains within FokI. Waugh and Sauer
later showed that single-amino-acid substitutions
could uncouple the DNA binding and scission
activities of FokI [11,12]. We analyzed the DNA-
binding mode of FokI restriction enzyme in the
absence of magnesium ions by DNA footprinting,
which showed a lack of protection at the cut site
[8,13].
Wah et al. later reported the crystal structures of
the native FokI and FokI bound to DNA [14,15]. The
structures confirmed the modular nature of FokI
endonuclease (Fig. 3a). They also revealed that the
cleavage domain is sequestered by the recognition
domain, thereby, restricting it from making any DNA
contacts. The structures were consistent with the
Fig. 3. Crystal structure of FokI and FokI bound to DNA.
(a) Structure of FokI–DNA complex and FokI enzyme
alone. In both structures, the FokI cleavage domain
piggybacks on the recognition domain. (b) Native FokI
crystallizes as a dimer. The dimer interface is at the FokI
nuclease domains, which is formed by two salt bridges
between arginine (R) and aspartic acid (D) residues of the
FokI monomers. Figure adapted from Wah et al., 1998.
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cleavage domain did not make any sequence-specific
DNA contacts at the cut site. Thus, the crystal
structure was amazingly in complete agreement
with the model derived from rigorous biochemical
studies.First chimeric restriction endonuclease
The bipartite nature of FokI endonuclease
suggested that it might be feasible to construct chimeric
nucleases with novel sequence specificities by linking
other naturally occurring DNA-binding proteins to the
cleavage domain of FokI endonuclease. This indeed
proved to be the case. We constructed the first
“chimeric” restriction endonuclease by linking the
Drosophila Ubx homeodomain to the cleavage domain
of FokI [16]. We then demonstrated the creation ofother novel site-specific endonucleases by linking zinc
finger proteins (ZFPs) (see below) and the N-terminal
147 amino acids of the yeastGal4 protein, respectively,
to the cleavage domain of FokI [17,18]. Thus, all three
eukaryotic DNA-binding motifs known at that time,
namely the helix–turn–helix motif, the zinc finger (ZF)
motif and the basic helix–loop–helix protein containing
a leucine zipper motif, were converted into novel site-
specific endonucleases [16–18]. Such engineered
chimeric nucleases were shown to make specific
cuts in vitro very close to their cognate sites [16–
19]. Yang-Gyun Kim, working as a post-doctoral
fellow in Alex Rich's laboratory, reported the
construction of Z–DNA conformation-specific endo-
nuclease [20,21].ZFNs (1996)
ZF motifs
Klug and co-workers reported the discovery of
repetitive zinc-binding domains in transcription factor
IIIA from Xenopus oocytes, which were later termed
ZF motifs [22]. Each ZF is composed of ~30 amino
acid residues containing two invariant pairs of
cysteines and histidines that bind a zinc atom. ZFs
are highly prevalent in eukaryotes. Pavletich and
Pabo reported the crystal structure of a set of three
fingers from the mouse transcription factor Zif268 in
complex with its target DNA, and this gave a glimpse
of how the ZFs recognize their cognate sites (Fig. 4)
[23]. The structure of the ZF was consistent with the
proposed structure for the zinc-binding domains [24].
The 30-amino-acid Cys2His2 ZF fold is a unique ββα
structure that is stabilized by a zinc ion [23]. Each ZF
usually recognizes 3- to 4-bp sequence and binds
DNA by inserting the α-helix into the major groove of
the double helix. The crystal structure suggested
that amino acids within the α-helix (positions −1, +1,
+2, +3, +5 and +6) of the ZF could be changed while
conserving the remaining amino acids as a consen-
sus backbone to generate ZFs with new sequence
specificities (Fig. 4). Most ZFs make contact with
their target 3-bp site; however, when there is an
aspartic acid residue present at +2 position of the
α-helix, it can enforce an adenine or a cytosine base
outside the 3-bp site at the next base on the
non-contact strand of DNA via a cross-strand
contact, changing the ZFs recognition to a 4-bp
site (Fig. 4). This ZF contact outside the 3-bp site
further influences the specificity of neighboring ZFs,
complicating the generation of ZFPs by simple
modular design, where each ZF recognizes a triplet
sequence. Therefore, design and selection of each
ZF has to be performed in a context-dependent
fashion to obtain highly sequence specific ZFPs,
which is laborious and time consuming. Normally,
Fig. 4. DNA recognition by ZFPs. (a) Structure of a single ZF, (b) DNA recognition by ZFs and (c) Structure of 3-finger
Zif268 bound to its cognate site. Figure adapted from Pabo et al., 2001, and Miller and Pabo, 2001.
967Review: Programmable Nucleases for Genome Engineeringthree to six such ZFs are linked together in tandem to
generate a ZFP that binds to a 9- to 18-bp target site
(Fig. 4).
With the publication of the crystal structure of
Zif268–DNA complex, scientists attempted to iden-
tify unique ZFs that specifically recognize each of
the 64 possible DNA triplets using phage display
[25–35]. Inherent in this concept was the assumption
that each ZF within a ZFP acts independent of its
neighbors to bind its cognate sequence. Scientists
reasoned that, by linking different ZFs selected in
such a way in tandem, one would be able to design
ZFPs that bind to any desired target DNA site within
a complex genome. Thus, one could unravel the
ZFP–DNA recognition code, if one exists in nature.
Early selection schemes kept the first and the third
modules of a 3-finger ZFP constant to generate a
library of 3-finger ZFP mutants with new sequence
specificities by varying the amino acids within the
α-helix (positions −1, +1, +2, +3, +5 and +6) of the
second ZF while conserving the remaining amino
acids as a consensus backbone. Selection of the
variants that bound strongly to a desired 9-bp target
site was performed using phage display to identify
ZFs that supposedly bound specifically to 5′-GNN-3′,
5′-ANN-3′, 5′-CNN-3′ and 5′-TNN-3′ triplets [31–35].
Although early attempts at modular design of
3-finger ZFPs using ZFs recognizing 5′-GNN-3′triplets were somewhat successful, further attempts
to generate highly specific ZFPs by including other
ZFs identified for the 5′-ANN-3′, 5′-CNN-3′ and
5′-TNN-3′ triplets did not yield the requisite specificity
for their target sites. A high degree of failure ensued
with these ZFPs, which became apparent when
these ZFPs were fused to FokI cleavage domain to
form ZFNs (see below). It soon became clear that the
recognition of DNA by the ZFs was not truly modular
as one had expected and that each ZF's recognition
was greatly influenced by its neighbors [36–39].
Generation of a library of mutants by changing of the
amino acids within the α-helices (positions −1, +1,
+2, +3, +5 and +6) simultaneously of all three ZFs to
incorporate the contribution from its neighbors was
simply not feasible because of the huge number of
mutants in such a library (1.27 × 1025) and due to
the practical limit of E. coli transformation efficiency
(~109 to 1011).
Once the limitations of the modular assembly of
ZFPs became apparent [29,37], scientists began to
develop alternate strategies to select individual fingers
in the context of their neighbors to generate highly
specific ZFPs for the desired target sites. Two suc-
cessful strategies were “sequential” selection and
“bipartite” selection. In sequential selection, individ-
ual ZFs are selected in the context of their
neighbors, thereby, circumventing the constraints
968 Review: Programmable Nucleases for Genome Engineeringof the modular assembly [29,40,41]. However, this
requires construction of multiple ZFP libraries and
multiple selections for each and every ZFP that is
desired. The bipartite approach is a variation of
the sequential selection, which utilizes two
pre-generated ZFP libraries wherein one-and-a-half
fingers of a 3-finger ZFP are partially randomized at
the key residues (α-helix positions −1, +1, +2, +3, +5
and +6) that make contact with DNA [40,41]. The
N-terminal half of the ZFP is randomized in one library
while the C-terminal half is randomized in the other.
Selection is performed in parallel using the 5′ and 3′
halves respectively of the target sequence. Selections
from the individual libraries are then recombined and
selected again using the full target site to obtain the
ZFP with the desired specificity. Although both these
approaches yield high-affinity ZFPs, they are too labor
intensive and cumbersome to perform routinely.
Furthermore, the selection approaches become un-
tenable with increasing number of ZFs within ZFPs,
since this will result in exponential increase in the
number of ZFP mutants, all of which cannot be
sampled in a single phage display selection experi-
ment. Improved DNA-binding specificity of polyzinc
finger peptides was also achieved by using strings of
two finger units [40]. Greater target specificity was
achieved by the way in which ZF arrays are
constructed—linking three 2-finger domains rather
that two 3-finger domains—resulting in far greater
target specificity through increased discrimination
against mutated or closely related sequences.
The phage display strategies require several
rounds of ZFP selection and they do not occur in
an in vivo setting. Alternate cell-based selection
strategies such as the bacterial one- and two-hybrid
systems, as well as the yeast two-hybrid system, link
the ZFP–DNA interaction to the transcriptional
activation of a reporter gene [42–45]. The advantage
of these systems over the phage display system is
that the high-affinity ZFPs for the desired target sites
can be identified in a single round of selection and it
is performed in an in vivo setting, even though the
bacterial systems do not account for chromatin. As
with all genetic reporter systems, the protein activity
(i.e., the binding affinity of a ZFP) in a particular clone
is coupled to the transcription of a reporter,
assuming that the protein concentration in the cell
does not vary greatly from clone to clone. The cell-
based selection strategies are discussed in detail
elsewhere [46].
Creation of ZFNs as “programmable” nucleases
ZFPs offered an attractive framework for designing
chimeric restriction enzymes with tailor-made
sequence specificities (Fig. 5a). We reasoned that
one could create designer nucleases that will cut DNA
at any preferred site by making ZFP fusions to the
FokI cleavage domain.We started by engineering twonovel chimeric nucleases (which were later renamed
as ZFNs) by fusing two 3-finger proteins, Sp1-QNR
and CP-QDR with different sequence specificities, to
the FokI cleavage domain to form Sp1-QNR-FN and
CP-QDR-FN, respectively [17]. Their cleavage spec-
ificities were tested by digesting the 48-kb λ genome.
Both ZFNs cut at specific sites within the λ genome.
CP-QDR-FN preferentially bound 5′-GAG GAG
GCT-3′, which is one of the four predicted consensus
sites present in the λ genome. Sp1-QNR-FN did not
bind to any of the four predicted consensus sites in the
λ genome but preferentially bound to 5′-GAG GGA
TGT-3′ that occurs only once in the λ genome [17].
Later, we showed that the fusion of the FokI cleavage
domain to a ZFP did not influence the sequence
specificity of the ZFP and did not alter its binding
affinity significantly [47]. During the performance of
these experiments, one observation that needed
more scrutiny stood out: cleavage by ZFNs required
a large excess of the purified enzyme over the DNA
substrate carrying a single recognition site, hinting to
the possibility of ZFN dimer formation (see below).
Mechanism of DNA cleavage by ZFNs
As we constructed additional ZFNs using ZFPs
assembled from published ZFs of known triplet
sequence specificities and tested them, they also
did not cut at the predicted consensus target sites
but elsewhere in the λ genome. We observed that
the cut sites, however, had some resemblance to
inverted repeats that appeared to contain partial ZFN
recognition sites. This implied that the FokI cleavage
domain may be binding at degenerate sites and
possibly functioning as a dimer. Soon afterwards,
the structure of native enzyme was published in
1998 [15], which showed FokI crystallized as a dimer
and the protein–protein interaction occurred at the
dimer interface formed by the cleavage domains via
two symmetrical salt bridges between arginine
(487R) and aspartic acid (483D) residues (Fig. 3b).
The kinetics of substrate cleavage by FokI restriction
enzyme provided additional support that FokI dimer-
ization is required for DNA cleavage [48,49].
After seeing our publication on the creation of
ZFNs in Proceedings of the National Academy of
Sciences [17], Dana Carroll approached us for a
collaboration to test stimulation of homologous
recombination (HR) in frog oocytes by a ZFN-
induced DSB. Since our laboratory focus was also
to target specific genes within cells [16], we agreed
to such collaboration. Initially, we purified two ZFNs
with known sequence specificities and shipped them
by FEDEX to the Carroll laboratory for testing
enhancement of intramolecular recombination
events in an extrachromosomal plasmid substrate
encoding ZFN target sites, by microinjection of ZFNs
and substrate into frog oocytes. Since the purified
ZFNs were not very stable, we purified the ZFNs
(a) ZFNs 
(b) TALENs 
(c) CRISPR/Cas9 
Fig. 5. A schematic diagram depicting programmable nucleases recognizing their target sites. (a) 4-finger ZFNs, (b)
TALENs and (c) RNA-guided CRISPR-Cas9. Figure adapted from Ramalingam et al., 2013.
969Review: Programmable Nucleases for Genome Engineeringalmost every 3 weeks or so to ship them to Utah.
This was quite tedious and a time-consuming effort,
especially for a small laboratory like ours. Later, we
provided Carroll laboratory with our ZFN constructs,
which they used to develop other ZFN derivatives
(by swapping the ZFPs) to use in their Drosophila
experiments. Our collaboration with the Carroll
laboratory lasted about 5 years and resulted in two
noteworthy publications [50,51], setting the stage for
genome engineering using programmable
nucleases.We investigated in more detail the requirements
for double-strand cleavage, both in vitro [50] and in
vivo [51] (see below), by Zif-QQR-FN and Zif-QNK-
FN enzymes that recognize 5′-GGG GAA GAA-3′
and 5′-GGG GCG GAA-3′ sites, respectively. We
constructed and tested a collection of varying number
and orientation of their canonical binding sites encoded
in a plasmid. At enzyme:substrate ratio close to 1, a
single copy of the recognition site did not support
cleavage. Only paired inverted sites in the tail-to-tail
orientation showed efficient double-strand cleavage,
970 Review: Programmable Nucleases for Genome Engineeringestablishing that these were the preferred substrates
for ZFNs (Fig. 5) [50]. The cleavage efficiency of the
inverted repeats also showed an exponential depen-
dence on ZFN concentration. At substantially higher
enzyme:substrate ratios, both ZFNs cut DNA that
carried a single copy of their recognition site. At high
enzyme concentrations, one molecule of ZFN is
probably bound specifically to the recognition site.
Dimerization of the cleavage domains occurs through
interaction either with a ZFN molecule that is bound
non-specifically to DNA in close proximity or with a ZFN
molecule in solution, promoting double-strand cleav-
age. Substitution of the amino acid residues [arginine
(R) or aspartic acid (D)] that form the symmetrical
salt bridges at the dimer interface with alanine (A)
completely abolishedZFNcleavage activity, confirming
that dimerization of the FokI cleavage domains is
required for activity [50].We also examined the kinetics
of DNA cleavage by Zif-QNK-FN in detail to gain insight
into how ZFNs cleave DNA and how two inverted sites
promote double-strand cleavage [52]. Substrate
cleavage was not first order with respect to the
concentration of Zif-QNK-FN, indicating that dou-
ble-strand cleavage required dimerization of the
cleavage domain. Thus, these findings that cleav-
age domains of ZFNs must dimerize to effect
efficient double-strand cleavage complemented
the observations from the natural FokI enzyme
[48,49]. In contrast to ZFNs, which preferred paired
inverted repeats as substrates for efficient cleavage,
the natural FokI enzyme cut single sites with very
high efficiency. The requirement for inverted paired
binding sites in close proximity distinguishes ZFNs
from FokI. In the latter case, it appears that
dimerization occurs between monomers bound to
quite distant sites on the DNA [48,49].
ZFPs fusion to other functional moieties
While we were the first to fuse the FokI cleavage
domain to ZFPs with a focus to develop ZFNs as
tools for genome engineering, other laboratories
have shown that ZFPs could be fused to other
functional moieties such as activator and repressor
domains to form hybrid proteins that function either
as zinc finger transcription activators (ZFAs) or as
zinc finger transcription repressors (ZFRs) within
cells [28,31,53–55]. Tim Bestor's group showed
that cytosine methylation could be targeted to
pre-determined sequences by fusing a CpG-specific
DNA methyltransferase to Zif268 to form zinc finger
methylases (ZFMs) [56].
The mechanism of action by ZFNs (Fig. 5) is quite
distinct from those of ZFAs, ZFRs and ZFMs. Two
ZFNs are required to bind to two recognition sites in
an inverted tail-to-tail orientation to promote an
efficient double-strand cleavage [50,51]. ZFAs,
ZFRs and ZFMs, on the other hand, bind to a single
recognition site for their activity [54–56]. Theimplications from the observation that ZFNs require
two copies of an inverted site to produce a DSB was
tremendous; it meant that 3-finger ZFNs effectively
have an 18-bp recognition site that is large enough to
target a unique genomic address for cleavage within
plant and mammalian cells. It also signified that two
ZFNs with different sequence specificities could
collaborate to cleave in tandem to produce a DSB
when their binding sites are appropriately positioned
and oriented with respect to each other within a
genome (Fig. 5) [50,51,57]. Later, we developed a
similar concept for split heterodimeric DNA methyl-
ases as a platform for creating designer ZFMs for
targeted DNA methylation in cells, in collaboration
with the Ostermeier laboratory at The Johns Hopkins
University [58].
Stimulation of HR in frog oocytes by targeted
cleavage using ZFNs
We tested the ZFNs for their ability to find and cleave
their target sites in living cells [51]. The engineered
extrachromosomal plasmid DNA substrates and the
nucleases when injected into Xenopus laevis oocyte
nuclei showed DNA cleavage and subsequent HR.
Specific cleavage required two inverted copies of the
ZFN recognition site in close proximity, reflecting the
need for dimerization of the FokI cleavage domains
for double-strand cleavage; these results were
consistent with the in vitro studies [50]. Cleaved
DNA substrates were activated for HR in oocytes,
and under optimum conditions, almost 100% of the
substrate recombined, even though the substrate
DNA was assembled into chromatin. We also
showed that two ZFNs, namely Zif-QQR-FN and
Zif-QNK-FN with different binding specificities, could
collaborate in vivo to stimulate recombination by
cleaving at the inverted hybrid recognition site [51].
Because the recognition specificity of ZFPs can be
altered experimentally, this foundational work estab-
lished the potential for inducing targeted recombination
in a variety of organisms and ushered in the era of
genome engineering.
After the successful collaborative effort with the
Carroll laboratory, our laboratory focus turned to
therapeutic applications of ZFNs for targeted
correction of disease-causing mutations in human
stem cells, particularly those of monogenic dis-
eases [59–65]. The Carroll laboratory went on to
pursue applying the technology in Drosophila and
other organisms (see Dana's reflections below)
[66–70].
Genome engineering of mouse melanocytes and
human cells using designed ZFNs
It was quite clear to us early on that facile
production of ZFNs and rapid characterization of
their in vitro sequence-specific cleavage properties
971Review: Programmable Nucleases for Genome Engineeringwas a pre-requisite before ZFN-mediated gene
targeting could become an efficient and effective
practical tool for widespread use in biotechnology.
Around 2000, we proceeded to use modular design
to engineer ZFNs that target specific endogenous
sequences within two mouse genes (mTYR and
mCFTR) and two human genes (hCCR5 and
hDMPK), respectively [59]. We were particularly
interested in targeting the CCR5 locus of the human
genome for two reasons: (1) CCR5 is a co-receptor
involved in HIV-1 infection of macrophages and T
cells. Homozygous inactivating mutations of
CCR5 are present in a subset of healthy humans,
and CCR5 was thought to be dispensable for
normal cellular differentiation and function [71].
We reasoned that CCR5 could potentially be an
attractive therapeutic target for future gene ther-
apy to treat and/or prevent HIV/AIDS by knocking
out both alleles of the CCR5 gene in patient-
derived hematopoietic pluripotent stem cells. (2)
More importantly, we reasoned that ZFN-mediated
inactivating mutations of CCR5 should not affect
the biology of human pluripotent stem cells (hPSCs)
and CCR5 could potentially serve as a safe harbor
locus for targeted addition of a therapeutic gene for
functional protein complementation (i.e., for gene
activation) in cells with the corresponding recessive
monogenic defects.
The ZFN designs for the four targets were based
largely on ZFs that recognize 5′-GNN-3′ triplets. We
showed that the engineered ZFN constructs recog-
nize their respective cognate DNA sites encoded in
a plasmid substrate in a sequence-specific manner
and induce a DSB [59]. However, when we tested
the mTYR ZFNs for gene correction at the endog-
enous locus of albino mouse melanocytes by HDR,
they were too toxic to cells. Although we observed
pigmented cells by microscopy, as early as 4 days
post-nucleofection of albino mouse melanocytes
using mTYR ZFPs fused to wild-type FokI cleavage
domains and the correcting donor, the number of
pigmented cells started to decline rapidly with time.
Similarly, when we tested hCCR5 ZFNs for CCR5
gene disruption in human cells by NHEJ, they also
proved to be highly toxic to cells. Subsequent attempts
to reduce ZFNs toxicity by regulated expression of
ZFNs using Tet-Off system in melanocytes and
model the allosteric control of FokI nuclease domain
into ZFNs by incorporating more of the linker region
were not successful [72].
In 2003, Mathew Porteus in David Baltimore's
laboratory published a gene targeting reporter
system in cultured human cells based on HDR of
a mutant GFP gene that was interrupted by a target
for 3-finger ZFNs of known sequence specificity
[73]. Using the 3-finger ZFNs that we provided to
him, he showed that the expression of ZFNs in the
presence of a correcting donor led to a consider-
able enhancement of GFP-positive cells via HDR.He also observed a decline of GFP-positive cells
with time, indicating ZFN toxicity due to off-target
cleavage [73].
In 2005, the first successful targeting of an
endogenous gene in human cells was accomplished
by scientists at Sangamo Biosciences [74]. They
chose to target the IL-2Rγ gene that is found
mutated in some X-linked severe combined immu-
nodeficiency patients. They designed a pair of
4-finger ZFNs that was very effective in inducing
both mutations by NHEJ and sequence replace-
ments by HDR. They also showed that further
refinement of ZFNs for specificity improved the
targeting efficiency [74].
ZFN toxicity, through cleavage at off-target sites,
was first shown in experiments with Drosophila [66].
Several laboratories including ours independently
observed ZFN toxicity while performing gene target-
ing in mammalian cells [72–74]. Since only two
copies are available for most genes in cells for
targeting, we reasoned that the ZFN toxicity was
more likely from induction of multiple DSBs in the
genome due to ZFNs binding to inverted partial or
degenerate sites. The toxicity issue becomes more
acute especially with increasing concentration of
ZFNs in cells due to their continued expression from
the transfected plasmids encoding them. ZFN
toxicity could be lowered either by selecting highly
specific ZFPs or by increasing the number of ZFs
within ZFNs to increase sequence specificity.
Alternatively, one could re-design the dimer inter-
face of the FokI cleavage domains to generate
heterodimer variants that will actively cleave only at
heterodimer binding sites and not at the homodimer
or single sites. We had previously shown that the
activity of the ZFNs could be abolished by mutating
the amino acid residues that form the salt bridges at
the FokI dimer interface [50]. Both of these
approaches were successfully employed by scien-
tists to increase the sequence specificity of ZFNs
and lower cytotoxicity [75–77].
After seeing the reports from Sangamo scientists
[75] and the Cathomen laboratory [76] in 2007, we
generated mTYR and hCCR5 ZFNs with obligate
heterodimer FokI nuclease domain variants (see
below) to reduce toxicity. We tested the re-designed
pairs of 3-finger hCCR5-ZFNs and mTYR-ZFNs
using the GFP gene targeting reporter system.
Both readily yielded GFP-positive cells, indicating
gene correction by HDR; they also showed greatly
reduced cytotoxicity [62]. These studies clearly
established that the sequence specificity of the
designed ZFNs was the major determinant of ZFN
activity for efficient gene targeting and reduced
cytotoxicity. The potential of ZFN technology appli-
cations for human therapeutics thus depended on
the ability to produce ZFNs that cleave the target
sequences with exquisite sequence specificity and
low cytotoxicity.
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does not yield highly specific ZFNs, we developed a
one-hybrid bacterial reporter system for interrogation
of ZFP–DNA interactions, in collaboration with Marc
Ostermeier's laboratory at Johns Hopkins University
[45]. While this approach yielded specific 3-finger
ZFNs, it was tedious and time consuming like other
similar efforts (see above). Later studies by other
laboratories confirmed our findings that ZFNs
generated by modular assembly does not always
yield highly specific ZFNs [78].
High-throughput generation of ZFNs
For high-throughput generation of ZFNs, further
refinements to cell-based screening strategies for
ZFPs were needed. They include selecting a desired
ZFP from a restricted library of functional ZFPs
where each member has been previously shown
experimentally to bind to its target with high affinity
and specificity. The functional ZFPs are chosen from
a collection that has been accumulated in a
database. Two such strategies are oligomerized
pool engineering (OPEN) reported by the Zinc Finger
Consortium led by Keith Joung [79] and context-
dependent assembly (CoDA) [80]. The OPEN
strategy utilizes an archive of zinc finger pools,
each consisting of a small number (~95 or fewer) of
different fingers designed to bind to a particular
3-bp subsite. For OPEN selection, a combinatorial
library of multi-finger arrays from these pools is
generated for a target 9-bp sequence of interest.
Members of this library, which bind efficiently to the
target site, are then isolated using a bacterial
two-hybrid selection system. This approach has
been shown to identify multi-finger ZFPs that
possess high affinities and specificities for the
target site. However, OPEN requires that a new
library of ZFP variants to be constructed and
screened for each and every new target site, which
is tedious and time consuming, limiting its utility for
widespread use. CoDA essentially is an extension of
the OPEN method in that it uses the hundreds of
functional ZFPs that were generated and tested in the
OPEN database to simplify the selection of a 3-finger
ZFP for a new target site. It works as follows: for each
central finger, one identifies 15–20 context-dependent
combinations of N-terminal finger 1 and finger 2 and
15–20 context-dependent combinations of C-terminal
finger 2 and finger 3, each of which has been shown to
function well in a bacterial two-hybrid DNA-binding
assay. The rationale here is that joining these sets
through a common central finger will be sufficient to
include any context-dependent interactions between
all three fingers of the ZFP that is eventually selected
for the desired target site. The authors reported a
success rate of N75% for ZFPs selected using CoDA
[80]. Using a variety of approaches including the
bipartite approach, Sangamo Biosciences has as-sembled a proprietary database of functional ZFPs
and ZF pairs from which they appear to be able to
select and refine highly specific ZFPs for a desired
target site.
Zinc finger nickases (ZFNickases)
Unlike engineered ZFNs, custom ZFNickases
cleave only one pre-determined DNA strand of a
targeted site. Conversion of ZFNs into ZFNickases is
achieved by inactivating the catalytic activity of one
monomer in a ZFN dimer [81,82]. ZFNickases
possess robust strand-specific nicking activity in
vitro. Furthermore, ZFNickases also stimulate ho-
mology directed repair at their nicking site in human
cells, albeit at a frequency lower than that by DSBs
using ZFNs [83]. Importantly, ZFNickases appear to
induce greatly reduced levels of mutagenic NHEJ at
their target nicking site as compared to ZFNs; this is
likely because nicks are not efficient substrates for
NHEJ.TALENs (2010)
Discovery of TALE motifs
TALENs [84–86] resulted from the fortuitous
discovery of a novel TALE DNA-binding module
that is found in plant virulence factors from Xantho-
monas bacteria [87,88]. The TALE central repeat
domain consists of repeating units of 33–35 amino
acids (Fig. 5b). Each repeat is largely identical
except for two highly variable amino acids at
positions 12 and 13, referred to as the repeat
variable di-residues (RVDs). While each ZF recog-
nizes 3–4 bases, each TALE motif recognizes a
single nucleotide, and the recognition specificity is
determined by the RVD (amino acid residue NI
recognizes A, HD recognizes C, NG or HG
recognizes T and NN recognizes G or A) (Fig. 5b).
Unlike the ZFs, the recognition of DNA by individual
TALEmodules appears to be largely independent of
neighboring modules. The DNA recognition code
thus provides a one-to-one correspondence be-
tween the array of amino acid repeats and the
nucleotide sequence of the DNA target (Fig. 5)
[89,90]. This simple DNA recognition code and the
modular nature of TALE motifs made them ideal for
constructing custom nucleases [91].
Transcription activator-like effector nucleases
The TALENs are designed in a modular style
similar to ZFNs, building largely upon the experience
gained from ZFN development (Fig. 5b). TALENs
are also able to target unique loci in complex
mammalian genomes. While ZFNs use the ZFs as
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motifs as the DNA recognition modules, but both use
the FokI catalytic domain as the DNA cleavage
module. Many laboratories including ours have
shown that TALENs have the same efficiency of
cutting as ZFNs when targeted to the same genomic
locus but often appear to have slightly lower
cytotoxicity [63,65].
Although TALENs are easier to generate than ZFNs,
the genes encoding TALENs are about three times
larger than ZFNs; this is because the TALE motifs are
similar in size to ZFs but recognize a single base, while
ZFs recognize 3- to 4-bp sequences. Furthermore, the
invariant and highly repetitive nature of TALE consen-
sus sequences, except for the two amino acid residues
knownasRVDs,makes itmore difficult to assemble the
genes encoding for TALENs in E. coli. Virus-mediated
delivery of large highly repetitive genes encoding
TALENs into mammalian cells is also problematic
[92]. Initial commercial pricing for TALENs was also
high (~$5000 per target), putting it beyond the reach of
small laboratories. But, before TALENs could really
take hold as a viable alternative to ZFNs, the
CRISPR-Cas9 approach was already on the
horizon.CRISPR-Cas9 (2012)
Discovery of adaptive immunity in bacteria and
archaea
Several excellent recent reviews describing the
discovery of adaptive immunity in bacteria and the
development of CRISPR-Cas9 for genome engi-
neering are available in literature [93–96]. Briefly,
bacteria and archaea have evolved an adaptive
defense mechanism that uses the CRISPR-Cas
system to degrade complementary sequences pres-
ent within invading viral and plasmid DNAs. Type II
CRISPR-Cas systems rely on the integration of
foreign DNA fragments into clustered regularly inter-
spaced short palindromic repeat (CRISPR) loci upon
transcription and processing result in short
CRISPR RNAs (crRNAs), which then anneal to a
trans-activating crRNA (tracrRNA) enabling Cas
proteins to direct sequence-specific degradation of
the foreign DNA [97].
Applications of CRISPR-Cas9 for
genome engineering
Gasiunas and co-workers reported that the Cas9–
crRNA complex functions as an RNA-guided endo-
nuclease with RNA-directed target sequence recog-
nition and protein-mediated DNA cleavage, paving
the way for engineering of universal programmable
RNA-guided DNA endonucleases [98]. In elegantwork, Doudna, Charpentier and co-workers showed
that Cas9 endonuclease-mediated cleavage de-
pends on tracrRNA and can also function efficiently
using a fusion of crRNA and tracrRNA to form a
single guide RNA (sgRNA), which greatly simplified
the application of CRISPR-Cas9 system for genome
engineering (Fig. 5c) [99]. Several groups then
showed that they could engineer the Type II bacterial
CRISPR-Cas9 system to function with custom
sgRNA in human cells to direct sequence-specific
cleavage [100–103]. The targeting efficiency of the
endogenous loci in human cells was comparable to
or better than that observed with TALENs or ZFNs
targeting the same loci. These laboratories also
showed that, upon simultaneous introduction of
multiple sgRNAs into human cells, they could achieve
multiplex gene editing of targeted loci of the genome.
They also generated Cas9 mutant nucleases called
nickases, to generate only single-strand breaks at a
targeted locus to promote HR while minimizing
NHEJ-mediated mutagenesis [100,101]. Thus, the
improvements to the CRISPR-Cas9 system that
include nicking enzymes, catalytically inactive Cas9
fusion to FokI cleavage domain [104,105] and
split-Cas9 [106], have followed a very similar path as
that blazed by ZFN development and ZFP methyl-
transferase fusions [58].
Unlike ZFNs and TALENs, which require design
and protein engineering of two nucleases, CRISPR-
Cas9 depends on RNA–DNA recognition for ge-
nome engineering. RNA design is much simpler and
easier when compared to protein engineering of two
nucleases each recognizing a half-site of a genomic
target sequence as in the case of ZFNs or TALENs.
The advantages of the CRISPR-Cas9 system
include its ease of RNA design for new targets, the
dependence on a single, constant Cas9 protein and
the ability to address many targets simultaneously
with multiple guide RNAs. These have led to its wide
adoption in research laboratories around the world.
The CRISPR-Cas9 methodology is also very inex-
pensive, making it very affordable by small labora-
tories. Because of these features, many successful
applications of the technology to genome engineer-
ing have rapidly ensued.
Not long after the demonstration that CRISPR-
Cas9 was effective in mammalian cells, several
groups noted that target mutagenesis was often
accompanied by cleavage and mutagenesis at
secondary sites [107–110]. The level of off-target
effects varied considerably among different targets,
perhaps as a function of sgRNA design. The
specificity of Cas9 cleavage has been enhanced
by the use of paired nickases, which enforce
recognition by two sgRNAs [109,163]. This makes
Cas9 resemble ZFNs and TALENs. Another ap-
proach has been to truncate the sgRNAs so that 17–
19 bases, rather than 20, match the target [111]. The
thinking here is that one or a few mismatches in a
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Design of sgRNAs with a GG motif at the 3′ end of
target specific sequences also appears to dramat-
ically enhance genome editing by CRISPR-Cas9 in
Caenorhabditis elegans [112].
Genome engineering of hPSCs using
programmable nucleases
hPSCs are especially well-suited for genome
engineering using programmable nucleases be-
cause they can undergo extensive cell culture
manipulations while still maintaining their pluripo-
tency and genome stability. The discovery that
somatic cells can be reprogrammed to human
induced pluripotent stem cells (hiPSCs) further
enhanced the prospect of using genome engineering
to correct genetic diseases in patient-derived cells.
For these reasons, autologous transplantation of
disease-corrected hiPSC-derived precursors was
hailed as the future of regenerative medicine. This
potential for personalized cell therapy led many
laboratories to concentrate their efforts to this end.
Several laboratories have used the nuclease plat-
forms for gene disruption and gene correction of a
variety of precursors and disease-specific hiPSCs
[113–124].
After completing the work on genome engineering
of human cells [62], our laboratory focus turned to
hiPSCs with the aim to address the following: (1)
could we generate genetically well-defined hiPSCs
by targeted addition of pluripotency genes to the
CCR5 locus of human fibroblasts and cord blood
mononuclear cells, using programmable nucleases?
This is in contrast to existing methods that use
random integration of stem cell factor genes into the
human genome for reprogramming. (2) Is it possible
to generate hiPSCs with bi-allelic CCR5 knockout
using this approach, to potentially treat HIV? (3) After
reprogramming, could the remaining wild-type CCR5
allele in single-allele CCR5-modified (heterozygous)
hiPSCs be used for gene activation—that is expres-
sion of a therapeutic gene? (4) Could the generation
of hiPSCs be performed with simultaneous gene
correction using programmable nucleases to simplify
treatment?
We used ZFN-mediated gene targeting to gener-
ate both single-allele and bi-allele CCR5-modified
hiPSCs from human lung fibroblasts (IMR90 cells)
and human primary cord blood mononuclear cells by
site-specific insertion of stem cell transcription factor
genes flanked by loxP sites at the endogenous
CCR5 locus [63]. Subsequent Cre recombinase
treatment of the CCR5-modified hiPSCs resulted in
the removal of the pluripotency transgenes, leaving
a loxP site in place. Further, we achieved genetic
engineering of the single-allele CCR5-modified
hiPSCs by site-specific addition of the large CFTR
transcription unit to the remaining CCR5 wild-typeallele, using CCR5-specific ZFNs. CFTR was
expressed efficiently from the endogenous CCR5
locus of the CCR5-modified hiPSCs [63].
Later, we successfully generated both cystic
fibrosis (CF) and Gaucher's disease (GD) hiPSCs,
respectively, from CF [homozygous for CFTRΔF508
mutation] and Type II GD [homozygous for β-gluco-
cerebrosidase 1448T N C mutation] patient-derived
fibroblasts, using CCR5-specific TALENs (Fig. 6)
[65]. Site-specific addition of loxP-flanked Oct4/
Sox2/Klf4/Lin28/Nanog gene cassette at the en-
dogenous CCR5 locus of primary fibroblasts induced
reprogramming, giving rise to both mono-allele (het-
erozygous) and bi-allele CCR5-modified hiPSCs [65].
Like many other laboratories before us, we also
demonstrated site-specific correction of sickle cell
disease (SCD) mutation at the endogenous HBB
locus of patient-specific hiPSCs [TNC1 line that is
homozygous for mutated β-globin alleles (βS/βS)],
using HBB-specific TALENs (Fig. 6) [65]. SCD-cor-
rected hiPSC lines showed gene conversion of the
mutated βS into the wild-type βA in one of the HBB
alleles, while the other allele retained the mutant
sequence. Excision of the loxP-flanked DNA cas-
sette from the SCD-corrected hiPSC lines resulted in
secondary heterozygous βS/βA hiPSCs, which
express the wild-type (βA) transcript to 30–40% level
as compared to uncorrected (βS/βS) SCD hiPSCs
when differentiated into erythroid cells [65]. ZFN/
TALEN-mediated generation and genetic correction
of disease-specific hiPSCs did not induce any
off-target mutations at closely related sites.
The results from these studies suggest that it is
feasible to use ZFN/TALEN/CRISPR-Cas9-evoked
strategies to (1) generate precisely targeted genet-
ically well-defined patient-specific hiPSCs, (2) re-
shape the function single-allele CCR5-modified
hiPSCs by targeted addition and expression of
therapeutic genes from the CCR5 chromosomal
locus for autologous cell-based transgene correction
therapy to possibly treat various recessive mono-
genic human diseases and (3) correct disease-caus-
ing mutations in hiPSCs. It also points to the future
possibility of combining generation of hiPSCs with
simultaneous gene correction in a single treatment.
The CRISPR-Cas9 system is probably best suited to
accomplish this. Several technical challenges that
need to be addressed before successful translation
of these strategies to human therapeutics still remain.
For example, protocols for quantitative differentiation of
hiPSCs into hematopoietic stem cells and isolation of
purified hematopoietic stem cells away from any
residual contaminating hiPSCs for transplantation are
yet to be worked out.
In a review article published in Biological Chem-
istry in 1999 [57], we had anticipated the upcoming
genome engineering revolution in biology and
medicine by the application of a ZFN-induced
targeted DSB in cells, including gene correction in
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Fig. 6. TALEN-mediated generation of CF and GD hiPSCs from patient-derived fibroblasts. (a) Schematic diagram
depicts the two-step protocol that was used to generate GD hiPSCs. In a first step, the donor containing five stem cell factor
genes (OSKLN: Oct4, Sox2, Klf4, Lin8 and Nanog) and eGFP was inserted at the safe harbor CCR5 locus (using
CCR5-specific TALENs) to reprogram the patient-derived fibroblasts. In a second step, the loxP site-flanked donor was
excised from the CCR5-modified CF and GD hiPSCs by treatment with Cre recombinase. CCR5-specific ZFNs have also
been used similarly to generate of hiPSCs from human fibroblasts and cord blood cells. (b) Bright field images of the
morphology of CF and GD hiPSCs generated using CCR5-specific TALENs. Characterization of GD hiPSCs by Oct4/
Sox2/Nanog/Tra-1-60 immunostaining and 4′,6-diamidino-2-phenylindole staining are also shown. (c) TALEN-mediated
correction of SCD hiPSCs. Mono-allele correction of homozygous HBB mutation of patient-specific SCD hiPSCs (TNC1
line) was achieved using HBB-specific TALENs and wild-type HBB donor construct. Mono-allele gene correction was
confirmed by sequencing the HBB locus. Parts of figure adapted from Ramalingam et al., 2014.
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Fig. 6 (continued).
976 Review: Programmable Nucleases for Genome EngineeringhPSCs as a form of targeted gene therapy: “The
availability of chimeric nucleases, a new type of
molecular scissors that target a specific site within
the human genome, will likely contribute and greatly
aid the feasibility of genome engineering and, in
particular, ex vivo gene therapy using stem cells”.
Through tireless efforts of numerous scientists
around the world, most of the predictions about the
applications using custom nucleases have come
true.
ZFNs sparked the genome engineering revolution
by first establishing that targeted modification of
custom sites in mammalian cells including the
human cells was possible. The development of
competing TALENs and CRISPR-Cas9 systems has
fueled the genome engineering revolution further by
making nuclease-based genome engineering much
simpler and easier and thereby extending it to small
laboratories. It is now possible to target specific
genes for cleavage within human cells and to
generate mutant organisms on demand for disease
models (see Dana's reflections below). Perhaps, the
greatest impact of genome engineering using
programmable nucleases will likely be felt in
agriculture and animal husbandry, provided that
GMO organisms become accepted (see Dana's
reflections below). Also, ex vivo genome engineering
of pluripotent stem cells using ZFNs is inching its
way to the clinic, largely through the efforts of
Sangamo scientists and their collaborators. Be-
cause of the potential for off-target effects, human
therapeutic applications will likely depend on risk
versus benefit analysis and informed consent. But,
we are yet to define what an “acceptable” or
“minimum” risk is. We define the minimum riskprofile as a list of NHEJ mutations in regions of the
human genome that, if they result from treatment,
would not adversely affect the well-being of the
patient. When this profile is worked out, targeted
genome engineering using pluripotent stem cells as
a form of cell-based gene therapy could be used
routinely in clinical practice, signifying a paradigm
shift in the treatment of human diseases, with the
potential to “cure” some of them.Reflections on the Origins and Uses of
Programmable Nucleases for Genome
Engineering—Dana Carroll
Zinc finger nucleases
For me, the story of the programmable nucleases
begins with envy—envy of those people working with
yeast and mice, who could make targeted genomic
modifications with relative ease and success. In both
systems, the modifications depended on HR be-
tween a genomic target and an exogenous donor
DNA supplied by the experimenter. Also in both
systems, the absolute frequency of the recombina-
tion events was very low, but the desired products
could be recovered by strong selection. To translate
this type of gene targeting to other organisms, it was
clear that the frequency of recombination had to be
improved.
It seemed clear that the barrier to enhancing
recombination was the fact that an intact genomic
target was essentially inert. Recombination is a mode
of DNA repair, and if there is no damage, there is no
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in the abstract of reagents that would have separate
DNA recognition and damaging elements [125]. In
collaboration with Peter Glazer and colleagues at Yale
University, we worked on triplex-forming oligonucleo-
tides linked toapsoralenmoiety that creates interstrand
cross-links—potentially recombinagenic damage
[126,127]. Some enhancement was seen, and elabo-
rations of this approach are still being pursued [128],
but the frequencies were still rather low.
By the late 1980s and mid-1990s, several studies
had made it clear that a frank, intentional DNA DSB
stimulates recombination with a homologous donor
DNA. Also, in many systems, repair of the break by
NHEJ often leads to production of local insertion and
deletion mutations. The pioneering experiments with
the meganucleases HO and I-SceI required the
introduction of the corresponding recognition sites
into the genome before cleavage by the subse-
quently provided enzyme [3,129–131]. To general-
ize this approach to arbitrary targets, we needed
cleavage reagents that could be programmed to
recognize novel sequences while retaining high
specificity.
When the paper from the Chandrasegaran labo-
ratory describing the ZF-FokI fusions appeared in
1996 [17], we thought that they had promise. We
knew about ZFs and their modular style of DNA
recognition, and linkage to a non-specific cleavage
domain created just the type of reagent we envi-
sioned. I quickly phoned Chandra and established a
collaboration to test the capabilities of these chimeric
restriction enzymes (now ZFNs) in eukaryotic cells.
As described in more detail by Chandra, we learned
about the requirement for dimerization of the
cleavage domain and the utility of paired binding
sites. We also examined the relationship between
the linker separating the domains of the protein and
the spacing between ZF binding sites and made a
molecular model to account for the findings [50].
Importantly for subsequent research, we showed
that the ZFNs very effectively cleaved their sub-
strates in the nucleus of a living cell—the X. laevis
oocyte—and initiated efficient recombination of
appropriately designed substrates [51]. It was not
certain ahead of time that this would work. While ZFs
are components of many natural eukaryotic tran-
scription factors, FokI is a bacterial enzyme; thus, its
cleavage domain would never have been challenged
with a substrate assembled into chromatin. Remark-
ably, both cleavage and recombination approached
100% in this system.
ZFNs in Drosophila
Once the basic requirements for ZFN cleavage
were established, it was time to try them in a whole
organism on an endogenous genomic target. This
presented a number of potential stumbling blocks.Success in the Xenopus oocyte experiments indi-
cated that chromatin per se would not be a barrier
but that system was essentially synthetic. The target
was in a plasmid DNA that had been injected into
the nucleus and, although assembled into chroma-
tin, might not have been identical to chromosomal
structures. The ZFNs were ones of known specific-
ity, and the targets were constructed to match them;
genuine genomic targets would require new ZF
combinations that might or might not be effective. In
whatever organism we decided to test the ZFNs, we
would have to deliver them and designed donor
DNAs appropriately.
We made the fortunate choice to talk with Kent
Golic about applying the ZFNs in the fruit fly,
Drosophila melanogaster. He and Yikang Rong
had just devised a gene targeting method for flies
that was based on producing a linear donor DNA in
situ [132]. We proposed to enhance this approach by
cutting the target with ZFNs, which would
(if successful) yield targeted mutations via NHEJ,
as well as increasing the frequency of homologous
repair.
Kent recommended that we try the yellow (y) gene
as our initial target. The mutant phenotype is very
easily scored, even in somatic mosaics, since its
product acts cell autonomously; he and Rong had
targeted it successfully in their experiments. Marina
Bibikova found a site in the second exon of y that
looked like a plausible target for two 3-finger ZFNs. It
was composed of two 9-bp sequences made up of
GNN triplets, for which ZFs had been identified in
Carlos Barbas's laboratory and separated by the
optimal distance of 6 bp. Starting with plasmids
supplied by Carlos and Dave Segal, who was by then
a post-doctoral in that laboratory, Marina produced
coding sequences for the required 3-finger sets and
linked each of them to the coding sequence of the FokI
cleavage domain from the Chandrasegaran plasmids
[17]. Following Kent's advice, these ZFN genes—yA
and yB—were placed in P element vectors under the
control of a Drosophila heat shock promoter.
In the Golic laboratory, we established yA and yB
transgenes in the genomes of separate stocks.
Marina crossed yA flies with yB flies and subjected
the larval offspring to a heat shock. Initially, all the
heat-shocked larvae died, and this was true of larvae
carrying only yA but not yB alone. When we
moderated the heat shock temperature to 34 °C,
rather than 37 °C, most of the larvae survived and
emerged as healthy adult flies [66].
The y gene is on the Drosophila X chromosome;
thus, we hoped that we might see evidence of
mutations in males after ZFN induction. In the first
batch of heat shock survivors, Marina saw a fly with a
mottled cuticle that she thought might indicate
somatic mutagenesis [66]. I was not experienced
enough to make a definitive call; thus, we invited
Kent to the microscope. After a quick look, he stood
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pretty excited”. On the strength of that one fly, I
bought celebratory wine for Kent's laboratory and my
own. We found several more somatic mosaics in
that first experiment and showed that the mutation
was heritable in some cases, indicating that we had
successfully targeted the germ line. DNA sequenc-
ing of several of the induced mutations showed that
they were exactly the indels expected for error-prone
NHEJ [66].
We then combined expression of the y ZFNs with
the Golic method for delivering a marked donor DNA
[132]. Remarkably, we achieved quite good levels of
HR with only a single copy of the donor delivered in
situ, either in circular or (even better) in linear form
[67]. The enhancement over providing the linear
donor alone was up to 100-fold, establishing the
principle that has guided nuclease-based genome
engineering ever since. ZFNs for the next two
Drosophila genomic targets we attacked (brown,
bw and rosy, ry) were also successful [70]. I
sometimes wonder what we would have done if the
ZFNs for y had failed. Would we have persisted
or concluded that the approach was not going to
work?
In a later study, we showed that we could achieve
efficient ZFN targeting—both NHEJ and HDR—by
direct embryo injection of mRNAs for the proteins
and an appropriate donor DNA [133]. This obviated
the need for extensive strain construction, and the
injections could be made into any strain background.
The approach of embryo injection is also a method of
choice for many other organisms.
ZFNs in other organisms
There was nothing about the ZFN-mediated
stimulation of targeted mutagenesis and gene
replacement that was specific to flies, except the
mode of delivery. Therefore, we were eager to try the
approach in other organisms that lacked a useful
gene targeting method. A collaboration with Gary
Drews' laboratory demonstrated that ZFNs worked
well in the model plant, Arabidopsis thaliana [68]. In
this case, we targeted an integrated synthetic
substrate, not an endogenous genomic target, with
characterized ZFNs and only assessed NHEJ
mutagenesis. Nonetheless, this showed that ZFN s
were active in plants and that the challenge of
delivery could be solved [68]. At the same time, Dan
Voytas and colleagues demonstrated the utility of
ZFNs in tobacco cells [134]. These experiments also
employed a synthetic target and ZFs of known
specificity but demonstrated homologous repair and
the regeneration of whole plants from modified calli.
The nematode, C. elegans, was and remains a
very popular experimental organism for studies of
development, neurobiology and other areas, but
researchers were reliant on random mutagenesis forgenetic studies. Jason Morton and I collaborated
with Erik Jorgensen and Wayne Davis to demon-
strate high levels of cleavage and mutagenesis by
ZFNs at both a synthetic extrachromosomal target
and an endogenous genomic target [69]. The latter,
like our experiments with Drosophila genes, involved
the construction of novel sets of ZFs. We were
frustrated, however, with our inability to produce
heritable mutations. C. elegans was notorious for
resisting the expression of transgenes in the germ
line, and we never overcame that limitation despite
considerable effort. Particularly with the advent of
the more efficient TALEN and CRISPR-Cas9 plat-
forms, many laboratories have now made germ-line
modifications—both by NHEJ and by homologous
repair—in the worms [135–137]. With the idea of
evading RNA interference in the C. elegans germ
line, I suggested to Jin-Soo Kim the approach of
injecting pre-formed Cas9-sgRNA ribonucleoprotein
instead of DNA vectors or mRNA. He and his
collaborators showed this to work well [138], and
ribonucleoprotein delivery has since been used very
effectively in mammalian cells [139,140].
The first application of ZFNs tomammalian cells was
made by Matt Porteus in David Baltimore's laboratory
[73]. He inactivated a GFP gene by inserting recogni-
tion sites for characterized ZF sets and showed that
cleavageby the correspondingenzymesstimulated the
restoration of fluorescence by recombination with a
donor DNA fragment. The first attack on a human
genomic target was reported by Urnov et al. in 2005
[74]. They achieved a homologous replacement
frequency of almost 20% at the IL-2Rγ locus and, in
the process, signaled the interest of Sangamo Biosci-
ences in tackling human disease genes.
Another ZFN success story was the application to
rats [141,142]. That organism was, and still is, in
common use for physiological studies, including drug
testing, but had no useful embryonic stem cells and
thus no gene targeting method comparable to that in
mice. Geurts et al. producedmutations in an integrated
GFP gene and two endogenous loci by injecting ZFN
plasmids or mRNAs into one-cell embryos and were
able to demonstrate germ-line transmission of the
modification [141]. ZFNs were also adopted for
genome engineering by embryo injection in mice,
where they have reduced the time and expense of
generating knockins and knockouts compared to the
classical embryonic stem cell technology [143–145].
Effective ZFN mutagenesis was demonstrated in a
variety of other species, including zebrafish [146,147]
and other model organisms, crop plants and food
animals (reviewed in Refs. [148–150]).Successor Technologies
Although ZFNs were put to good use in many
organisms, the technology was not broadly adopted
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ZF sets for new genomic targets. We were very
fortunate that our first three designs for Drosophila
targets all worked because we eventually had
success with only 5 out of 12 attempts. Validated
ZFNs were made available for purchase, but only at
a price that was prohibitive for many laboratories.
Several different schemes were developed for
selection of ZF combinations, but these required
considerable expertise and resources, as Chandra
has described above. The anticipated code of ZF–
DNA recognition [37] never materialized.
Great excitement was generated by the discovery
of a simple recognition code in a novel class of
proteins, the transcription activator-like effectors
(TALEs or TAL effectors) [87,88]. When some
pathogenic bacteria, particularly of the genus
Xanthomonas, infect plants, they inject these TALE
proteins into host cells, where they enter the
nucleus, bind to promoter regions of host genes
and alter their activity in ways that promote the
infection. The DNA-binding regions of these proteins
are composed of tandem 34-amino-acid repeats.
When enough protein–target pairs had been char-
acterized, it emerged that each repeat module
recognizes a single base pair, and the most common
repeats comprise a simple, robust recognition code.
Well before any structural analysis was performed to
confirm the mode of recognition [89,90], the analogy
to ZFs was obvious, and several groups linked sets
of TALE modules to the FokI cleavage domain,
producing TALENs that were very effective in
targeted genome cleavage [84–86]. Like ZFNs, the
TALENs must be delivered in pairs to satisfy the
requirement for dimerization.
When crystal structures of TALE clusters bound to
DNA were published [89,90], they clarified how 34
amino acids (somewhat more than a single ZF) could
be folded and polymerized to contact individual base
pairs. Surprisingly, only one of the two amino acids that
constitute the recognition code actually projects into the
major groove; the other side chain bends back and
makes contacts that stabilize the structure of the
module. Furthermore, only two of the modules (for C
and G) make hydrogen bond contacts with the
corresponding base pairs; the others establish speci-
ficity by steric complementary and van der Waals
interactions. One of the features of TALE recognition is
that consecutive modules have much more contact
with each other than is seen with ZFs. This may be the
reason for the observation that single mismatches
between the protein andDNAhave a stronger effect on
affinity than might be expected [151]. If one or two
modules are out of register, this affects the interaction
with neighboring modules and disrupts the structure in
the vicinity. In this view, the energy of TALE binding
comes from the scaffold that DNA provides for a
favorable protein structure and relatively little from
direct protein–DNA interactions.The potential challenge to building new TALE
arrays—because of their repeat structure, they tend
to be unstable and cannot be PCR amplified—was
rapidly overcome by several assembly schemes,
and new TALEN designs can be produced routinely.
New designs are very often effective. In our study in
Drosophila, only 2 of 17 pairs tested failed to give
very usable levels of cleavage and mutagenesis
[152]. In a larger study in cultured human cells,
Reyon et al. had success at 84 of the 96 endogenous
genomic targets they attacked with TALENs [91].
These and other papers demonstrated that the TALE
recognition code is robust, TALE assembly is
routine, TALEN activity is reliably high and most
TALENs work as long as they can be delivered
effectively.
But pity the poor TALENs. Only 3 years after the
elucidation of the TALE recognition code, the
CRISPR-Cas platform arrived on the scene [99].
These tools emerged slowly from studies of odd
arrays of short repeat sequences that are found in
many bacterial and archaeal genomes [93–96]. As
described initially in the E. coli K12 genome,
repeated sequences of a few dozen base pairs
were found separated by unique spacer sequences
of similar length. Dubbed CRISPRs, these arrays
were accompanied by unique sets of protein-coding
genes, called cas for CRISPR associated. Nearly
20 years after their discovery, the spacers were
found to correspond to sequences from bacterial
viruses and plasmids, and this led to the hypothesis,
since confirmed, that CRISPR-Cas was an adaptive
immune system that defends against invading DNA
[153]. How the spacers are captured into the arrays
in the first place remains a subject of research.
In the simplest of the CRISPR systems, called Type
II, the CRISPR repeats are transcribed into a long
RNA that is processed into smaller pieces—crR-
NAs—that carry part of the repeat sequence and part
of a single spacer [93–96,154]. Binding of a transact-
ing RNA (tracrRNA) produced from elsewhere within
the CRISPR locus creates a complex that associates
with the Cas9 protein. This tripartite structure is an
enzyme that locates its DNA target by the presence of
a specific short sequence, called a PAM, for proto-
spacer-adjacent motif, and the presence just up-
stream from the PAM sequence of a sequence
complementary to the 5′ end of the spacer fragment
in the crRNA (Fig. 5c). Two nuclease active sites in
Cas9 then cut the two strands of the target DNA,
inactivating the invader. For the widely used Cas9
protein of Streptococcus pyogenes, the PAM that is
recognized in the target nGG, where n can be any
nucleotide, and the standard length of complementary
sequence in the crRNA is 20 nucleotides.
In 2012, Jinek et al. showed that the components
of this system could be used in purified form to cut
arbitrary DNA sequences by incorporating the
corresponding 20-nucleotide target sequence at
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fused the critical portions of the crRNA and tracrRNA
into a single guide RNA (sgRNA). In combination
with the Cas9 protein, this comprises a simple
two-component system for targeted cleavage. Hav-
ing the experience with ZFNs and TALENs as
precedents, with almost no delay, a number of
groups deployed the CRISPR tools in mammalian
cells [100–103], in zebrafish [155], in mice [156], in
fruit flies [157,158] and in a number of other
eukaryotic genomes. The remarkable simplicity of
CRISPR-Cas rapidly made it a favorite in laborato-
ries around the world. No protein engineering was
required, a teenager could design new sgRNAs for
new targets and multiple targets could be attacked
simultaneously. The high success rate helped
establish CRISPRs as the programmable nuclease
of choice for research. As many people have said,
this platform democratized genome engineering.Off-Target Effects
The first ZFNs for a genuine genomic target
revealed an issue that has continued to concern
the field. As noted above, expressing the ZFNs for
the yellow gene too enthusiastically was lethal to
flies [66]. This turned out to be a property of only one
of the proteins, yA; when it was expressed alone, it
was toxic. We later showed that this was due to
cleavage, since a mutation in the nuclease active
site relieved the toxicity (and any efficacy, of course)
[70]. This suggested that the ZFs of yA were able to
bind and form dimers at sequences other than those
for which they were designed, and cleavage at
secondary targets was the cause of the lethality.
Off-target cleavage has been confirmed in many
other situations, with TALENs and Cas9 as well, by
visualizing multiple repair foci induced by the
nucleases and by analyzing genomic sequences
for induced mutations.
In the case of CRISPR, it may be that tolerance of
one or a few mismatches is an important feature of
the system [159]. Viral genomes evolve rapidly, and
allowance for this fact provides immunity toward
viruses related, but not identical, to the ones that
established the CRISPR array. Something similar
may be true of TALEs; in the ongoing war between
pathogen and host, the bacterium needs scope to
respond to sequence changes at the target in the
host promoter. Perhaps similarly, eukaryotic tran-
scription factors that depend on recognition by ZFs
typically show a consensus binding sequence that is
not rigidly matched at all their targets. Thus, a lack of
perfect discrimination against off-target sequences
may be inherent in the recognition components of all
three platforms.
Schemes have been designed to enhance the
specificity of all the programmable nucleases. ForZFNs and TALENs, mutations have been introduced
at the dimer interface of the FokI cleavage domain
that allow heterodimers to form but not homodimers
[75–77,160]. This means that ZFNs such as yA are
no longer toxic, and it has been quite effective in
reducing off-target cleavage with many other de-
signs. With CRISPR-Cas9, truncating the guide
sequence has a positive effect on specificity
[111,161] apparently because a small number of
mismatches in a shorter duplex has a larger
destabilizing effect at secondary sites. Kim and
co-workers found that having two extra Gs at the 5′
end of the sgRNA that do not match the target
improved specificity without impairing on target
efficacy [162]. This maneuver may also somewhat
destabilize the RNA–DNA hybrid because the extra
nucleotides are not comfortably accommodated into
the Cas9 binding pocket. A mutation in one of the
nuclease active sites of Cas9 converts it into a
nicking enzyme. Providing two sgRNAs directed to
targets in close proximity on the DNA leads to paired
nicking, which has proved quite effective at inducing
both NHEJ and HDR while demanding recognition
by both guides simultaneously [109,163]. I particu-
larly like this scheme, as it essentially converts
CRISPR-Cas9 into an analog of ZFNs and TALENs,
which are naturally “paired nickases”. I still find it
remarkable, however, that nicks up to 100 bp apart
are still processed similar to a DSB in cells. Finally,
Cas9 inactivated at both active sites has been fused
to the FokI cleavage domain, producing an even
closer analog to ZFNs [104,105]. This construct also
requires simultaneous recognition of two binding
sites, with a consequent increase in specificity.
How much off-target cleavage matters depends on
the situation in which the programmable nucleases
are used. For many research applications, the
designed alteration in the target is most important,
and accommodation can be made for things going
on in the background. To attribute a phenotype to an
engineered change, however, one must use inde-
pendently derived mutated alleles, do extensive
out-crossing or rescue the phenotype by comple-
mentation. For applications to food organisms,
and particularly to human therapy, stringent criteria
must be applied, and out-crossing is not a sensible
option.
When cloned cells or whole organisms are used,
whole genome sequencing can reveal all induced
sequence changes. It must be remembered, how-
ever, that such changes accrue naturally during DNA
replication in every cell cycle. The only way to
confidently identify nuclease-induced off-target mu-
tations is to find indels (which are less common
during replication) at sites sufficiently related to the
designed target to be plausible recognition sites.
Whole genome sequencing of mixed cell popula-
tions would have to be very deep in order to reveal
infrequent, but potentially harmful, modifications.
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significance is challenging. Initially, people scanned
the genome for related sequences and analyzed
them individually by amplification and sequencing.
More recent methods capture cleavage sites more
broadly, and they are quite powerful and revealing,
but each has some limitations. The methods have
been reviewed very recently [164,165], and I have
only a few additional comments.
1. Lentiviral capture [166,167] is cumulative—
that is, the products are not re-cuttable; thus,
they accumulate with time. If on-target
cleavage is near saturation, off-target cap-
ture will continue to occur; thus, the latter
may be exaggerated. This method is not
applicable to all cells and organisms.
2. GUIDE-seq [161] captures breaks individu-
ally, but because the introduced duplex
oligonucleotide has protected ends, the
junctions show almost no insertions or
deletions in the target. How this affects
capture and the analogy to indel formation
is not known. Like lentiviral capture, this
method is cumulative.
3. The LAM-PCR HTGTS method of Frock et
al. uses the designed target to capture
secondary targets based on induced trans-
locations [168]. It has the advantage that it
does not depend on introduction of anything
exogenous beyond the nucleases them-
selves, and the junctions observed are
typical of NHEJ. On the other hand, it only
reports on events in cells that have seen at
least two more or less simultaneous breaks,
and this may over-estimate off-target cuts. It
is also cumulative.
4. Digenome-seq [162] requires a lot of very
deep sequencing.
5. BLESS takes a snapshot of breaks present
at the particular moment at which the cells
are harvested [169,170]. This will be influ-
enced by the timing relative to nuclease
delivery.
6. Someone should compare these methods
on the same set of samples.NHEJ versus HDR
All of the nuclease platforms depend on cellular
repair activities for their ultimate outcomes. As noted
above, the major pathways of DSB repair in most
organisms are NHEJ and HDR; and in most
experimental situations, NHEJ dominates. For sim-
ple targeted mutagenesis, this is fine, but it is oftenthe case that a particular sequence replacement
templated by a donor DNA is the desired product. In
favorable circumstances, HDR may account for 20–
30% of the repair products, and those products can
be isolated by molecular screening; but there are
organisms and cell types in which this frequency is
much lower, sometimes less than 1%. The balance
between HDR and NHEJ can be shifted by disabling
components of the major NHEJ pathway. For
example, we found that knocking out DNA ligase
IV in Drosophila raised the proportion of HDR products
from around 20% to about 65%, sometimes even
higher [133,171,172]. In the absence of ligase IV, indel
mutations characteristic of NHEJ were still recov-
ered; thus, there are clearly alternative routes to this
type of repair [173]. Other methods of reducing
ligase IV activity have also shown promise in
mammalian cells and embryos [174–176]. Because
homologous repair naturally occurs only in the S and
G2 phases of the cell cycle, when a sister chromatid
is present, cell synchronization has been used to
favor HDR with some success, but not in all cells
[74,177]. A general solution to the challenge of
enhancing HDR may not exist due to differences
among cell types, the overall complexity of repair
mechanisms and the difficulty in identifying factors
that limit each type of repair.Societal Applications
One of the most exciting aspects of ZFNs,
TALENs and CRISPR-Cas9 is how broadly they
have been used effectively [148–150]. They readily
modify genomic targets in model organisms (some
cited above), disease organisms, disease vectors,
crop plants, livestock and primates, including
humans (e.g., see Refs. [63,65,116,122] and [178–
187]). I am optimistic about the prospects in all these
arenas.
The programmable nucleases offer opportunities
for making beneficial changes in the genomes of
food organisms with precision and safety. In some
plant and animal species, loci that provide tolerance
to heat and drought have been identified. To moderate
the already irreversible effects of climate change and to
stabilize the food supply in threatened regions, we can
introduce the beneficial sequences into the genomes
of other breeds with molecular approaches, without
laborious and expensive crossing and back-crossing
[188]. While this is technically genetic modification, it
would not involve the introduction of whole genes in
most cases and certainly not genes from other species.
Muchof the current opposition toGMOs is basedon the
proprietary ownership of the organisms and the
politically insensitive way that seed companies have
taken advantage of crop producers. These consider-
ations have over-shadowed the benefits and essential
safety of the crops. What would have happened if the
Table 1. A comparison of programmable nuclease platforms
Programmable nucleases
(year of introduction)
ZFNs
(1996)
TALENs
(2010)
CRISPR-Cas9
(2012)
(1) Sequence recognition Protein–DNA Protein–DNA RNA–DNA
(2) Design and selection Tedious and time consuming
(protein engineering)
Easier than ZFNs
(protein engineering)
Simple
(RNA design)
(3) Commercial pricing Very expensive Expensive Cheap
(4) Targeting efficiency Variablea Moderate Highb
(5) Off-target effects Variablea Low Moderateb
(6) Multiple targets Difficult Difficult Easy
(7) Viral delivery Easy Moderate Moderate
a Depending on ZFN constructs, targeting efficiency and off-target effects can vary from high to low.
b These entries are somewhat subjective in nature. As with ZFNs, targeting efficiency and off-target effects can vary depending on
constructs and selected target site designs.
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provided essentially without conditions to farmers in the
third world? I doubt that much outcry would have been
heard.
Livestock improvement is also being undertaken
with nucleases [184,185]. Beyond this, there are
opportunities to use genome-edited pigs, in particular,
tomodel humangenetic diseases.Mousemodels have
been very informative, but in many cases, they do not
mimic the human phenotype. In size and physiology,
the pig is a closer match. In addition, pig organs have
beenused for xenotransplantation, but outcomes suffer
from immunological rejection. Methods are being
developed to grow essentially human organs in pigs
to overcome this limitation.
Finally, of course, there are applications to human
therapy under development. Using ZFNs prepared
at Sangamo Biosciences, one Phase I clinical trial is
already complete [123]. Circulating T cells were
isolated from HIV-infected patients, and the cells
were treated ex vivo with ZFNs targeting CCR5,
which codes for a co-receptor required for infection
by most HIV-1 strains. The cells were re-implanted in
the individuals from whom they came, and the
situation was monitored over a period of about
8 months and continued up to 42 months. The
patients were on anti-retroviral drug therapy during
most of the trial; thus, the efficacy of the ZFN
treatment per se was not assessed. Gratifyingly,
there were no adverse effects attributable to the
ZFN treatment; if off-target mutations were gener-
ated, they were benign. This experience highlights
several aspects of applying programmable nucle-
ases to the treatment of humans. Ex vivo treatment
of cells is much easier than delivering the nucleases
to tissues in vivo, it is easy to see how nuclease
treatment can be combined with stem cell therapies
once they are developed to a clinical stage and
knockouts via NHEJ are still easier than correction
by HDR. The next step for the CCR5 trial is to apply
the ZFNs to earlier precursors or even stem cells
[122,189].Which platform will ultimately be best for these
societal applications? This is not a trivial question
to answer (see Table 1). For most such purposes—
clinical or agricultural—an engineered nuclease will
be used repeatedly on many different individuals.
Efficacy and specificity are required, but all the
platforms have this capability, and generating the
nuclease will be a small part of the overall program;
thus, other considerations come into play. As
illustrated by the CCR5 trial, some highly evolved
ZFNs are very specific. TALENs seem to have the
highest inherent specificity [190–193], but there are
adjustments for ZFNs and CRISPR-Cas9, as de-
tailed above. The ZFNs are considerably smaller
than TALENs or Cas9; thus, delivery may be easier
in some contexts. Only a single, constant protein is
required in the CRISPR case, and multiple sgRNAs
can be delivered simultaneously, if several targets
need to be addressed. Smaller Cas9 proteins from
bacteria other than S. pyogenes also seem effective
[170,194], and this may ameliorate some delivery
problems.Genome Engineering of Human Embryos
In principle, whole-body correction of a disease
gene could be achieved by editing in human
fertilized eggs, but there are many ethical and
scientific issues that must be addressed before
taking this route. The experiments with monkeys
described above show that the fundamental tech-
nology is at hand. In addition, a very recent paper
reported the use of CRISPR-Cas9 in non-viable
human embryos [195]. Clinical applications, howev-
er, require extensive prior consideration and broad
discussion.
First, targeted changes made in zygotic genome
are permanent and heritable, unlike changes made
in somatic cells. Do we know enough about the
consequences of such alterations to undertake
them? Second, off-target modifications will also be
983Review: Programmable Nucleases for Genome Engineeringpermanent. Are we confident of the specificity of the
programmable nucleases? We would argue, not yet.
Third, this is a completely novel type of human
intervention into our own genetics. Is society ready to
adopt this audacious approach? Fourth, there are
alternative ways to treat genetic diseases, and in
vitro fertilized embryos can be screened as an
alternative to genome modification. What diseases,
if any, are candidates for germ-line editing? Fifth,
there will be people who want to use germ-line
editing for trivial and cosmetic traits, raising
the specter of eugenics. How can this powerful
yet daunting technology be confined to legitimate
uses?
Both of us believe, with many other scientists, that
human germ-line modification—especially of DNA in
the nucleus, the material that makes us who we
are—should remain out of bounds for research and
experimentation at present [196–198]. Mitochondrial
transplantation to treat mitochondrial diseases,
which has been approved by the British government,
is also heritable but involves only a small number of
non-nuclear genes.Acknowledgements
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